24/7 Market News Snapshot 17 September, 2024 – Capricor Therapeutics Inc (NASDAQ:CAPR)

September 17, 2024

DENVER, Colo., 17 September, 2024 (247marketnews.com) – (NASDAQ:CAPR) are discussed in this article.
Capricor Therapeutics Inc. (CAPR) has experienced remarkable trading activity, opening the day at $4.86 and reaching a current price of $5.065, signifying an impressive increase of approximately 14.85%. This surge follows a closing price of $4.41 in the prior session, indicative of strong investor optimism. Trading volume has also seen a significant uptick, with 1.40 million shares exchanged, suggesting a heightened interest in the stock. Analysts note that the latest price rally may indicate a breakthrough from prior resistance levels, potentially attracting further investment. Investors are encouraged to monitor ongoing volume trends and price fluctuations to evaluate the sustainability of CAPR’s upward trajectory.

In a notable advancement, Capricor Therapeutics has forged a pivotal partnership with Nippon Shinyaku Co., Ltd. to further the commercialization of its lead therapeutic candidate, deramiocel, designed for the treatment of Duchenne muscular dystrophy (DMD). As part of the recently established term sheet, Capricor is set to receive a $20 million upfront payment upon the finalization of a Definitive Agreement, along with an additional $15 million equity investment at a 20% premium. This collaboration potentially unlocks milestone payments up to $715 million, coupled with a substantial share of future product revenues.

The alliance significantly strengthens Capricor’s financial foundation, extending its operational runway into 2026, and positions the company to advance developmental activities and prepare for a commercial launch. Having demonstrated promising outcomes in earlier clinical studies, deramiocel is poised for broader market access, particularly in European territories alongside existing agreements in the U.S. and Japan.

Linda Marbán, Ph.D., CEO of Capricor, emphasized the partnership’s importance in enhancing treatment accessibility for DMD patients globally, while Nippon Shinyaku expressed commitment to accelerating the commercial potential of deramiocel, ultimately aiming to address critical needs in the DMD therapeutic landscape. Together, the two organizations are set to deliver impactful solutions for affected individuals.

Related news for (CAPR)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.